The FDA has formally endorsed the utilization of NephroCheck® (TIMP-2*IGFBP-7) as a biomarker for the purpose of predicting the risk of AKI, particularly within critical care settings [137]. The gene discussed is IGFBP7; the disease is acute kidney injury.